{"id":58451,"date":"2026-02-28T14:36:24","date_gmt":"2026-02-28T06:36:24","guid":{"rendered":"https:\/\/flcube.com\/?p=58451"},"modified":"2026-02-28T14:36:25","modified_gmt":"2026-02-28T06:36:25","slug":"shionogi-files-corectim-lotion-for-japan-approval-expands-topical-jak-inhibitor-franchise-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58451","title":{"rendered":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>Shionogi &amp; Co., Ltd.<\/strong> and subsidiary <strong>Torii Pharmaceutical Co., Ltd.<\/strong> announced the submission of a <strong>manufacturing and marketing approval application<\/strong> in <strong>Japan<\/strong> for <strong>CORECTIM (delgocitinib) 0.5% lotion<\/strong>, a <strong>non\u2011steroidal topical JAK inhibitor<\/strong> for <strong>atopic dermatitis (AD)<\/strong>. The new <strong>lotion formulation<\/strong> complements the <strong>already approved ointment<\/strong>, which is indicated for <strong>adults, children, and infants<\/strong> in Japan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-submission\">Regulatory Submission<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Shionogi &amp; Co., Ltd. + Torii Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CORECTIM (delgocitinib) 0.5% lotion<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Non\u2011steroidal topical JAK inhibitor<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>Manufacturing and marketing approval application (Japan)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Atopic dermatitis (AD)<\/td><\/tr><tr><td><strong>Formulation Status<\/strong><\/td><td>Lotion (new); Ointment (approved)<\/td><\/tr><tr><td><strong>Ointment Approval<\/strong><\/td><td>Adults, children, and infants (Japan)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corectim-franchise-in-japan\">CORECTIM Franchise in Japan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>First Approval<\/strong><\/td><td>January\u202f2020 \u2013 <strong>world&#8217;s first non\u2011steroidal topical JAK inhibitor<\/strong><\/td><\/tr><tr><td><strong>Current Indications (Ointment)<\/strong><\/td><td>Atopic dermatitis in adults, children, and infants<\/td><\/tr><tr><td><strong>Manufacturing\/Distribution<\/strong><\/td><td>Shionogi<\/td><\/tr><tr><td><strong>Distribution\/Promotion<\/strong><\/td><td>Torii Pharmaceutical (co\u2011promotion with Shionogi)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-licensing-leo-pharma-partnership\">Global Licensing \u2013 LEO Pharma Partnership<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>LEO Pharma (exclusive worldwide license, ex\u2011Japan)<\/td><\/tr><tr><td><strong>Licensed Rights<\/strong><\/td><td>Development and commercialization of topical skin preparations<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>2014<\/td><\/tr><tr><td><strong>Approved Indication (EU\/US)<\/strong><\/td><td>Chronic hand eczema<\/td><\/tr><tr><td><strong>Brand Name (EU\/US)<\/strong><\/td><td>Anzupgo Cream<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formulation Expansion:<\/strong> The <strong>lotion formulation<\/strong> addresses <strong>patient preference and application flexibility<\/strong>\u2014lotions offer easier spreadability for large surface areas vs. ointments, potentially improving adherence in <strong>widespread AD patients<\/strong>.<\/li>\n\n\n\n<li><strong>Pediatric Market Leadership:<\/strong> With <strong>infant approval<\/strong> for the ointment and anticipated lotion approval, Shionogi\/Torii strengthen <strong>Japan&#8217;s AD treatment paradigm<\/strong> across <strong>all age groups<\/strong>, capitalizing on <strong>steroid\u2011sparing demand<\/strong> from parents and physicians.<\/li>\n\n\n\n<li><strong>JAK Inhibitor Differentiation:<\/strong> As the <strong>world&#8217;s first topical JAK inhibitor<\/strong>, delgocitinib has <strong>first\u2011mover experience<\/strong>; the lotion extension maintains competitive edge vs. emerging topical JAKs (ruxolitinib cream, Opzelura) and emerging topical biologics.<\/li>\n\n\n\n<li><strong>Global Value Realization:<\/strong> The <strong>LEO Pharma partnership<\/strong> monetizes <strong>ex\u2011Japan rights<\/strong> while Shionogi retains <strong>domestic franchise control<\/strong>\u2014Anzupgo&#8217;s EU\/US chronic hand eczema approval validates global commercial potential beyond AD.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Japan AD Market<\/strong><\/td><td>~\u202f500,000+ patients; high steroid\u2011sparing demand; JAK inhibitors gaining preference over calcineurin inhibitors<\/td><\/tr><tr><td><strong>Topical JAK Competition<\/strong><\/td><td>Incyte&#8217;s Opzelura (ruxolitinib) approved in US; delgocitinib maintains Japan market leadership through formulation breadth<\/td><\/tr><tr><td><strong>Formulation Strategy<\/strong><\/td><td>Ointment (barrier repair) + Lotion (ease of use) = comprehensive topical portfolio addressing diverse patient needs<\/td><\/tr><tr><td><strong>LEO Pharma Synergies<\/strong><\/td><td>Anzupgo expansion to AD in EU\/US possible; chronic hand eczema approval establishes regulatory pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Japan approval timelines, lotion launch expectations, and formulation market share. Actual results may differ due to risks including regulatory review outcomes, competitive topical JAK launches, and pricing pressure in Japan&#8217;s reimbursement system.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58452,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,38,423,4631],"class_list":["post-58451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-market-approval-filings","tag-shionogi","tag-torii-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58451\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58451\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-28T06:36:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-28T06:36:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis\",\"datePublished\":\"2026-02-28T06:36:24+00:00\",\"dateModified\":\"2026-02-28T06:36:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2803.webp\",\"keywords\":[\"Auto-immune\",\"Market approval filings\",\"Shionogi\",\"Torii Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58451#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58451\",\"name\":\"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2803.webp\",\"datePublished\":\"2026-02-28T06:36:24+00:00\",\"dateModified\":\"2026-02-28T06:36:25+00:00\",\"description\":\"Shionogi & Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58451\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58451#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58451","og_locale":"en_US","og_type":"article","og_title":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis","og_description":"Shionogi & Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.","og_url":"https:\/\/flcube.com\/?p=58451","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-28T06:36:24+00:00","article_modified_time":"2026-02-28T06:36:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58451#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58451"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis","datePublished":"2026-02-28T06:36:24+00:00","dateModified":"2026-02-28T06:36:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58451"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58451#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","keywords":["Auto-immune","Market approval filings","Shionogi","Torii Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58451#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58451","url":"https:\/\/flcube.com\/?p=58451","name":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58451#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58451#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","datePublished":"2026-02-28T06:36:24+00:00","dateModified":"2026-02-28T06:36:25+00:00","description":"Shionogi & Co., Ltd. and subsidiary Torii Pharmaceutical Co., Ltd. announced the submission of a manufacturing and marketing approval application in Japan for CORECTIM (delgocitinib) 0.5% lotion, a non\u2011steroidal topical JAK inhibitor for atopic dermatitis (AD). The new lotion formulation complements the already approved ointment, which is indicated for adults, children, and infants in Japan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58451#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58451"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58451#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","width":1080,"height":608,"caption":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58451#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi Files CORECTIM Lotion for Japan Approval \u2013 Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58451"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58451\/revisions"}],"predecessor-version":[{"id":58453,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58451\/revisions\/58453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58452"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}